Background: Chronic daily headache (CDH) affects 2% to 4% of the North American and European population. Various pathways lead to this condition, although chronification of migraine and the occurrence of central sensitization in tension headache are the 2 most common. Medication overuse headaches complicate a substantial portion of other primary headaches that have become chronic and often make their treatment more complex and less successful.
Methods/results: A 10-step process to help primary care providers evaluate and treat CDH patients begins with excluding secondary headache disorders, then moves on to classification of the primary underlying headache disorder. Next, the exacerbating factors, as well as relevant comorbid conditions, are identified. The patient's current acute therapy is examined, and attempts are made to identify and resolve medication overuse if present. Past preventive therapies are reviewed, allowing for thoughtful design of a headache action plan with preventive, acute, and lifestyle components. Patients are asked to keep a headache diary, used to initiate a cycle of continuous improvement in a patient's response to acute and preventive therapeutic approaches.
Conclusions: A systematic approach and partnership with patients often make it possible to convert CDH to episodic headache that is responsive to both acute and preventive therapies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/head.12881 | DOI Listing |
JMIR Ment Health
January 2025
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
Background: Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment.
View Article and Find Full Text PDFJAMA Neurol
January 2025
Department of Neural and Pain Sciences, University of Maryland School of Dentistry, Baltimore.
Importance: Biomarkers would greatly assist decision-making in the diagnosis, prevention, and treatment of chronic pain.
Objective: To undertake analytical validation of a sensorimotor cortical biomarker signature for pain consisting of 2 measures: sensorimotor peak alpha frequency (PAF) and corticomotor excitability (CME).
Design, Setting, And Participants: This cohort study at a single center (Neuroscience Research Australia) recruited participants from November 2020 to October 2022 through notices placed online and at universities across Australia.
Curr Opin Oncol
January 2025
Gustave Roussy Departement Interdisciplinaire de Soins de Support aux Patients en Onco-hematologie, Villejuif, France.
Purpose Of Review: Immune checkpoint inhibitors (ICI) have become an integral part of oncology treatment. ICI currently has approval for more than thirty tumor types with proven efficacy. However, ICI can expose patients to inflammatory side effects, such as immuno-related adverse events (irAE).
View Article and Find Full Text PDFJ Patient Exp
January 2025
Veterans Health Administration Headache Centers of Excellence, US Department of Veterans Affairs, Orange, CT, USA.
In 2018, the Veterans Health Administration (VHA) established the original 19 Headache Centers of Excellence (HCoE) program, and an evaluation center. This study utilized a Veteran engagement group method to elicit input from Veteran patients living with chronic headache on daily needs, social determinants of health, and preferences and suggestions for headache programs, services, and research priorities. Four engagement groups were conducted between July 13 and August 22 of 2022 with Veterans who experience headache and received care at a VHA HCoE.
View Article and Find Full Text PDFReumatologia
December 2024
Óbuda University, Budapest, Hungary.
Introduction: Osteoarthritis (OA) presents significant challenges, imposing limitations on patients' daily activities. Factors such as restricted mobility, sedentary lifestyles, social isolation, and weight gain can exacerbate the difficulties faced by these individuals. Our study aimed to identify the needs and personal challenges faced by individuals with OA, and the impact of the COVID-19 pandemic.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!